Pharmaceuticals US

US Hemophilia Treatment Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

US Hemophilia Treatment Market Industry Trends and Forecast to 2034: Segmented by (Product, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

US · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $4.92 Bn Placeholder estimate
Estimate 2025 $5.02 Bn 35.7% of the global market
Projected 2034 $6.00 Bn 19.5% Adds $978.9 Mn over 9 forecast years
CAGR 2025–2034 2.0% Faster than 8% of 180 Pharmaceuticals markets here
Key players 6 +1
  • US is 35.69% of the global market.
  • In North America, the largest is US (this report) at $5.02 Bn.
  • Fastest growing: Canada at 3.9% a year.
  • US ranks 1st of 2 by size in North America.

Market size projection

US

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$978.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Hemophilia Treatment Market market size by year, US
YearMarket sizeChange that yearSince 2025
2024 (estimate) $4.92 Bn — —
2025 (base) $5.02 Bn +$98.4 Mn —
2026 (forecast) $5.12 Bn +$100.4 Mn +2%
2027 (forecast) $5.22 Bn +$102.4 Mn +4%
2028 (forecast) $5.32 Bn +$104.4 Mn +6.1%
2029 (forecast) $5.43 Bn +$106.5 Mn +8.2%
2030 (forecast) $5.54 Bn +$108.6 Mn +10.4%
2031 (forecast) $5.65 Bn +$110.8 Mn +12.6%
2032 (forecast) $5.76 Bn +$113.0 Mn +14.9%
2033 (forecast) $5.88 Bn +$115.3 Mn +17.2%
2034 (forecast) $6.00 Bn +$117.6 Mn +19.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

US Hemophilia Treatment Market Analysis at a glance
Market size, 2025$5.02 Bn placeholder estimate
Forecast, 2034$6.00 Bn placeholder estimate
Growth (CAGR), 2025–20342.0% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct, type and end user (see all)
Key playersRoche, Novo Nordisk A/S, Takeda Pharmaceutical Company Ltd, Sanofi, CSL Behring and 1 more (see all)
Regulator in the USFDASource: US Food and Drug Administration. Checked 14 Nov 2026.
Active clinical trials60 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The US Hemophilia Treatment Market Analysis Executive Summary

Hemophilia treatments prevent and treat bleeding in people whose blood does not clot properly, using factor products, antibodies and gene therapy.

Key segments of the hemophilia Treatment market include product (Factor Replacement, Non-Factor Therapies and Gene Therapy) and type (Hemophilia A and Hemophilia B).

Bar chart: US Hemophilia Treatment market size, 2024–2034, placeholder estimates. $4.92 Bn in 2024, $5.02 Bn in 2025 and $6.00 Bn in 2034, 2.0% CAGR.
US Hemophilia Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

US Hemophilia Treatment Market Dynamics

Market Growth Drivers

Better genetic diagnosis, orphan drug incentives, patient advocacy and new gene and enzyme therapies are driving the hemophilia Treatment market. More countries now have national rare disease plans.

Opportunity

Newborn genome screening, gene therapies and access programmes in emerging markets give the hemophilia Treatment market strong growth.

Market Restraints

Very small patient numbers, long diagnosis delays, high treatment prices and limited specialist centres hold back the hemophilia Treatment market.

Competitive Landscape for Hemophilia Treatment Market in US

The hemophilia Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Hemophilia Treatment Market in US

Hemophilia Treatment in the US: rules, payment and research

New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead.⁠[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).⁠[2] ClinicalTrials.gov lists 60 studies on Hemophilia Treatment that are recruiting, active or about to start in the US.⁠[3]

[1] US Food and Drug Administration. Checked 14 Nov 2026.

[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for hemophilia Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Hemophilia Treatment right now, from free public sources.

Latest research 208 papers since 2021 (worldwide)

  1. Coagulation Testing Practices and Guideline Adherence in Hemophilia A: A Retrospective Quality Assessment of a Dutch Expertise Hemophilia Treatment Center. Haemophilia : the official journal of the World Federation of Hemophilia, 2026
  2. Hemophilia: Carrier testing and therapy. Journal of family medicine and primary care, 2026
  3. [Basic research supporting discovery and lifecycle development of antibody therapeutics for hemophilia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2026
  4. Extravascular factor IX: a semicentennial narrative review. Research and practice in thrombosis and haemostasis, 2026
  5. Artificial Intelligence and Machine Learning in the Context of Hemophilia: A Scope Review. Haemophilia : the official journal of the World Federation of Hemophilia, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Hemophilia Treatment in context

The US compared

  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
  • People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Hemophilia Treatment market in the US?
Placeholder estimate: about $5.02 Bn in 2025, rising to about $6.00 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Hemophilia Treatment market in the US growing?
Placeholder estimate: about 2.0% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Hemophilia Treatment market report cover?
The report splits the market by product (Factor Replacement, Non-Factor Therapies, Gene Therapy), type (Hemophilia A, Hemophilia B) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Hemophilia Treatment market?
Key players include Roche, Novo Nordisk A/S, Takeda Pharmaceutical Company Ltd, Sanofi, CSL Behring and Pfizer Inc..
What is driving the Hemophilia Treatment market?
Better genetic diagnosis, orphan drug incentives, patient advocacy and new gene and enzyme therapies are driving the hemophilia Treatment market. More countries now have national rare disease plans.
Who regulates Hemophilia Treatment in the US?
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead. Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Hemophilia Treatment are running in the US?
60 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
How much research is published on Hemophilia Treatment?
PubMed lists 208 papers on Hemophilia Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in US

See all

Related on rare diseases and biologics and biosimilars

See the topic